Chronic liver disease: Global perspectives and future challenges to delivering quality health care

Seto, Wai‐Kay; Mandell, M. Susan

doi:10.1371/journal.pone.0243607

Cited by 18 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The liver is an important immune organ of the human body and contains numerous innate and adaptive immune cells ( 1 , 2 ). Liver diseases, including hepatitis, liver fibrosis, and hepatic carcinoma, pose serious challenges to global public health ( 3 ). Immune-mediated hepatic injury is a crucial step in the progression of liver diseases ( 4 , 5 ).…”

Section: Introductionmentioning

confidence: 99%

Corilagin Ameliorates Con A-Induced Hepatic Injury by Restricting M1 Macrophage Polarization

et al. 2022

View full text Add to dashboard Cite

Immune-mediated hepatic injury plays a key role in the initiation and pathogenesis of diverse liver diseases. However, treatment choice for immune-mediated hepatic injury remains limited. Corilagin, a natural ellagitannin extracted from various traditional Chinese medicines, has been demonstrated to exhibit multiple pharmacological activities, such as anti-inflammatory, anti-tumor, and hepatoprotective properties. The present study aimed to investigate the effects of corilagin on immune-mediated hepatic injury using a murine model of concanavalin A (Con A)-induced hepatitis, which is well-characterized to study acute immune-mediated hepatitis. Herein, mice were administered corilagin (25 mg/kg) intraperitoneally twice at 12 h intervals, and 1 h later, the mice were challenged with Con A (20 mg/kg body weight); serum and liver samples were collected after 12 h. The results showed that corilagin significantly increased the survival of mice and reduced serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels. In addition, corilagin markedly improved histopathological damage, hepatocyte apoptosis, and oxidative stress in the liver. The activation of M1 macrophages in the hepatic mononuclear cells was also significantly reduced compared with that in the control group. The expression of M1 macrophage-associated proinflammatory cytokines and genes, including interleukin (IL)-6, IL-12, and inducible nitric oxide synthase (iNOS), was also decreased after corilagin treatment. Finally, the results demonstrated that corilagin regulated macrophage polarization by modulating the mitogen-activated protein kinases (MAPK), nuclear factor (NF)-κB, and interferon regulatory factor (IRF) signaling pathways. Thus, the findings indicate that corilagin protects mice from Con A-induced immune-mediated hepatic injury by limiting M1 macrophage activation via the MAPK, NF-κB, and IRF signaling pathways, suggesting corilagin as a possible treatment choice for immune-mediated hepatic injury.

show abstract

Section: Introductionmentioning

confidence: 99%

Corilagin Ameliorates Con A-Induced Hepatic Injury by Restricting M1 Macrophage Polarization

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Liver disease is one of the leading causes of mortality worldwide and constitutes a wide range of diseases with varied or unknown etiologies. For instance, a study shows that in 2017 1.32 million deaths worldwide, or 2 to 4% of all annual deaths were caused directly due to cirrhosis [1]- [3]. With the help of automated decision-making methods using a machine learning model, the death caused due to liver disease can be reduced.…”

Section: Introductionmentioning

confidence: 99%

Random forest and support vector machine based hybrid liver disease detection

Assegie¹,

Rajkumar

Kumar

et al. 2022

Bulletin EEI

View full text Add to dashboard Cite

This study develops an automated liver disease detection system using a support vector machine and random forest detection techniques. These techniques are trained on data containing the information collected from the Mayo Clinic trial in primary biliary cirrhosis (PBC) of the liver conducted between 1974 and 1984. The proposed system can detect the presence of liver disease in the test set. The random forest model is used for recursive feature elimination at the pre-processing stage and the support vector machine is trained on the optimal feature set. The experimental result shows that the proposed support vector machine (SVM) model has achieved 78.3% accuracy.

show abstract

“…Chronic liver disease (CLD) remains a frequent cause of death. In 2017, 1.32 million people died directly because of liver cirrhosis, which accounts for 2–4% of deaths annually [ 2 , 3 ]. During the coronavirus disease 2019 (COVID-19) pandemic, mortality was also significantly higher in patients with CLD than in those without CLD [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and clinical significance of serum sodium variability in patients with acute-on-chronic liver diseases: a prospective multicenter study in China

Xue

Deng

et al. 2022

Hepatol Int

View full text Add to dashboard Cite

Background No reports exist regarding the prevalence of different Na levels and their relationship with 90-day prognosis in hospitalized patients with acute-on-chronic liver disease (AoCLD) in China. Therefore, the benefit of hyponatremia correction in AoCLD patients remains unclear. Methods We prospectively collected the data of 3970 patients with AoCLD from the CATCH-LIFE cohort in China. The prevalence of different Na levels (≤ 120; 120–135; 135–145; > 145) and their relationship with 90-day prognosis were analyzed. For hyponatremic patients, we measured Na levels on days 4 and 7 and compared their characteristics, based on whether hyponatremia was corrected. Results A total of 3880 patients were involved; 712 of those developed adverse outcomes within 90 days. There were 80 (2.06%) hypernatremic, 28 (0.72%) severe hyponatremic, and 813 (20.95%) mild hyponatremic patients at admission. After adjusting for all confounding factors, the risk of 90-day adverse outcomes decreased by 5% (odds ratio [OR] 0.95; 95% confidence interval [CI] 0.93–0.97; p < 0.001), 24% (OR 0.76; 95% CI 0.70–0.84; p < 0.001), and 42% (OR 0.58; 95% CI 0.49–0.70; p < 0.001) as Na level increased by 1, 5, and 10 mmol/L, respectively. Noncorrection of hyponatremia on days 4 and 7 was associated with 2.05-fold (hazard ratio [HR], 2.05; 95% CI, 1.50–2.79; p < 0.001) and 1.46-fold (HR 1.46; 95% CI 1.05–2.02; p = 0.028) higher risk of adverse outcomes. Conclusions Hyponatremia was an independent risk factor for a poor 90-day prognosis in patients with AoCLD. Failure to correct hyponatremia in a week after admission was often associated with increased mortality. (ClinicalTrials.gov number: NCT02457637, NCT03641872). Clinical Trial Numbers This study is registered at Shanghai www.clinicaltrials.org (NCT02457637 and NCT03641872). Supplementary Information The online version contains supplementary material available at 10.1007/s12072-021-10282-8.

show abstract

Chronic liver disease: Global perspectives and future challenges to delivering quality health care

Cited by 18 publications

References 13 publications

Corilagin Ameliorates Con A-Induced Hepatic Injury by Restricting M1 Macrophage Polarization

Corilagin Ameliorates Con A-Induced Hepatic Injury by Restricting M1 Macrophage Polarization

Random forest and support vector machine based hybrid liver disease detection

Prevalence and clinical significance of serum sodium variability in patients with acute-on-chronic liver diseases: a prospective multicenter study in China

Contact Info

Product

Resources

About